KPS Signs Licensing Agreement for Oral Mucositis Adjunct Therapy 'MucosaMin' for Cancer Patients in Taiwan

[Asia Economy Reporter Jang Hyowon] KPS's bio-subsidiary BigThink Therapeutics announced on the 24th that it has signed its first licensing agreement for the oral mucositis management topical solution 'MUCOSAMIN®' with a Taiwanese pharmaceutical company.

Han Migyeong, CEO of BigThink, stated, "Through the licensing agreement with the Taiwanese pharmaceutical company CHIFU, once product registration is completed within this year, it will be actively used as a treatment for cancer patients suffering from oral symptoms." She added, "CHIFU is a company that has introduced and sold major products from global pharmaceutical companies and recently established a foundation for patients suffering from cancer, making it a socially leading company providing the best treatment methods to cancer patients in Taiwan."

BigThink holds the Asian rights (Korea, Japan, Malaysia, Hong Kong, Singapore, Indonesia, Philippines, etc.) for MUCOSAMIN, which was developed by the Italian amino acid-specialized pharmaceutical company PDI (Professional Dietetics International S.r.l.). It is approved and sold in the European Union (EU), Israel, Jordan, Morocco, Iran, Vietnam, Nepal, and other countries. Simultaneous approval reviews are underway in Australia, New Zealand, Canada, Egypt, Turkey, and others.

According to PDI, the main ingredient of MUCOSAMIN, Sodium hyaluronate, prevents cell damage through antioxidant action and physically forms a protective barrier to aid wound regeneration. Additionally, the combination of amino acids (Glycine, L-Proline, L-Leucine, L-Lysine HCl, etc.), which are collagen precursors, helps recover mucosal ulcers and also protects fibroblasts.

Kim Hayong, CEO of KPS, said, "It is encouraging to announce the start of MUCOSAMIN's entry into Asia through the contract with CHIFU," adding, "We will complete licensing agreements for Japan and Southeast Asia within this year to accelerate BigThink's globalization."

He continued, "Currently, we are preparing for approval application in Korea, and together with the breast cancer new drug Nerlynx® tablets, which are scheduled for release in early February, it will be usefully applied for managing oral mucositis in cancer patients in the future."

This content was produced with the assistance of AI translation services.